Item 5.07. Submission of Matters to a Vote of Security Holders. On June 18, 2021, Selecta Biosciences, Inc. (the "Company") held its Annual Meeting of Stockholders. A total of 76,356,811 shares of the Company's common stock were present electronically or represented by proxy at the meeting, representing approximately 67.46% of the Company's outstanding common stock as of the April 21, 2021 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2021.



Item 1 - Election of three Class II Directors to serve until the 2024 Annual
Meeting of Stockholders, and until their respective successors have been duly
elected and qualified.
NOMINEE               Votes FOR    Votes WITHHELD     Broker Non-Votes
Göran Ando, M.D.      53,398,234      8,034,027          14,924,550
Carrie S. Cox         53,388,481      8,043,780          14,924,550
Aymeric Sallin        45,267,262     16,164,999          14,924,550



Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021.


 Votes FOR     Votes AGAINST    Votes ABSTAINED    Broker Non-Votes
 76,269,773       50,628            36,410                -



Based on the foregoing votes, Göran Ando, M.D., Carrie S. Cox, and Aymeric Sallin were elected as Class II Directors and Item 2 was approved.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses